Awakn Life Sciences: Key Patent Filed Covering Behavioral Addictions With Ketamine And Ketamine-Assisted Therapy May 27, 2022
Awakn Life Sciences Files Patent Cooperation Treaty (PCT) Application For The Treatment Of Behavioral Addictions May 26, 2022
Awakn Life Sciences CEO, Anthony Tennyson, Joins Dustin Robinson of Iter Investments for ‘The Investor… May 24, 2022
Awakn Life Sciences Completes The World’s First Ketamine Treatment Study For Behavioral Addictions May 20, 2022
Awakn Life Sciences Provides Shareholder Update on Three Operational Ketamine-Assisted Therapy Clinics in the UK and… Apr 13, 2022
